Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEP-DC Vaccine + Cyclophosphamide in Advanced NSCLC
NCT05195619Phase 1Active, not recruiting
- Sponsor
- Lausanne University Hospital
- Start
- Mar 2022
- Primary completion
- Jun 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of PEP-DC in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Lausanne University Hospital. Primary endpoints: Number of patients who receive at least one dose of vaccine at 3.5 years, Assessment of adverse events and 1 more. Started Mar 2022; status: active, not recruiting.
02
Drugs
PEP-DC
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05195619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05195619.